Alternative Interventional Study Designs

  • Stephen P. Glasser


There are many variations to the classical randomized controlled trial. These variations are utilized when, for a variety of reasons, the classical randomized controlled trial would be impossible, inappropriate, or impractical. Some of the variations are described in this chapter and include: equivalence and noninferiority trials; crossover trials; N of 1 trials, case-crossover trials, and externally controlled trials. Large simple trials, and prospective randomized, open-label, blinded endpoint trials are discussed in another chapter.


Beta Carotene Assay Sensitivity Crossover Design Investigational Drug Noninferiority Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Cited in Breslin JEcb. Quote Me. Ontario, CA: Hounslow Press; 1990.Google Scholar
  2. 2.
    Siegel JP. Equivalence and noninferiority trials. Am Heart J. Apr 2000; 139(4):S166–170.CrossRefGoogle Scholar
  3. 3.
    Assay Sensitivity. Wikipedia.Google Scholar
  4. 4.
    Snapinn SM. Noninferiority trials. Curr Control Trials Cardiovasc Med. 2000; 1(1):19–21.PubMedCrossRefGoogle Scholar
  5. 5.
    The International Conference on harmonization (ICH) Guidelines.Google Scholar
  6. 6.
    D’Agostino RB Sr., Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues–the encounters of academic consultants in statistics. Stat Med. Jan 30, 2003; 22(2):169–186.PubMedCrossRefGoogle Scholar
  7. 7.
    Wiens BL, Zhao W. The role of intention to treat in analysis of noninferiority studies. Clin Trials. 2007; 4(3):286–291.PubMedCrossRefGoogle Scholar
  8. 8.
    Diamond GA, Kaul S. An orwellian discourse on the meaning and measurement of noninferiority. Am J Cardiol. Jan 15, 2007; 99(2):284–287.PubMedCrossRefGoogle Scholar
  9. 9.
    Hennekens CH, Eberlein K. A randomized trial of aspirin and beta-carotene among U.S. physicians. Prev Med. Mar 1985; 14(2):165–168.PubMedCrossRefGoogle Scholar
  10. 10.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. July 17, 2002; 288(3):321–333.PubMedCrossRefGoogle Scholar
  11. 11.
    Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol. Jan 15, 1991; 133(2):144–153.PubMedGoogle Scholar
  12. 12.
    Hallqvist J, Moller J, Ahlbom A, Diderichsen F, Reuterwall C, de Faire U. Does heavy physical exertion trigger myocardial infarction? A case-crossover analysis nested in a population-based case-referent study. Am J Epidemiol. Mar 1, 2000; 151(5):459–467.PubMedGoogle Scholar
  13. 13.
    Olson CM, Fontanarosa PB. Advancing cardiac resuscitation: lessons from externally controlled trials. JAMA. Apr 7, 1999; 281(13):1220–1222.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V 2008

Authors and Affiliations

  • Stephen P. Glasser
    • 1
  1. 1.Univesity of Alabama at Birmingham, Birmingham, AlabamaBirmingham

Personalised recommendations